Jacobs Levy Equity Management, Inc 89bio, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q1 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in 89bio, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 98,848 shares of ETNB stock, worth $950,917. This represents 0.0% of its overall portfolio holdings.
Number of Shares
98,848Holding current value
$950,917% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding ETNB
# of Institutions
208Shares Held
158MCall Options Held
366KPut Options Held
944K-
Janus Henderson Group PLC London, X020.5MShares$197 Million0.09% of portfolio
-
Ra Capital Management, L.P. Boston, MA19.9MShares$191 Million3.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.3MShares$138 Million4.56% of portfolio
-
Deep Track Capital, LP Greenwich, CT9.32MShares$89.6 Million2.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.16MShares$68.9 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $447M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...